Janssen-Cilag's Ionsys recalled because of self-activation
This article was originally published in Scrip
Janssen-Cilag (Johnson & Johnson) is recalling its transdermal fentanyl patch, Ionsys, 40μg/dose from the market in 14 countries, because some patches have been found to self-activate, which may potentially cause an overdose.
You may also be interested in...
Following safety issues raised by the US FDA, no toxicity concerns have emerged in preclinical studies of Newron’s candidate schizophrenia therapy, evenamide, and a clinical safety study has started to evaluate its CNS effects.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.